Evidence map›Paper›PMID 19480654›Full record

Trial reportTrials2009

VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome.

Ursula Thiem, Georg Heinze, Rudolf Segel, Thomas Perkmann, Franz Kainberger, Ferdinand Mühlbacher, Walter Hörl, Kyra Borchhardt

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Interventions for preventing bone disease in kidney transplant recipients.The Cochrane database of systematic reviews · 2019
    Review
  5. Review
  6. Review
  7. Article
  8. Current evidence on vitamin D deficiency and kidney transplant: What's new?Reviews in endocrine & metabolic disorders · 2017
    Review
  9. Article
  10. Review
  11. Review
  12. Vitamin D in renal transplantation - from biological mechanisms to clinical benefits.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014
    Review
  13. Review
  14. Article
  15. Review
  16. Clinical impact of hypercalcemia in kidney transplant.International journal of nephrology · 2011
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ursula ThiemDepartment of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. n0351588@students.meduniwien.ac.at
Georg Heinze
Rudolf Segel
Thomas Perkmann
Franz Kainberger
Ferdinand Mühlbacher
Walter Hörl
Kyra Borchhardt
Medical University of Vienna · ATVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D does not only regulate calcium homeostasis but also plays an important role as an immune modulator. It influences the immune system through the induction of immune shifts and regulatory cells resulting in immunologic tolerance. As such, vitamin D is thought to exert beneficial effects within the transplant setting, especially in kidney transplant recipients, considering the high prevalence of vitamin D deficiency in kidney transplant recipients. METHODS/

designThe VITA-D study, a randomized, placebo-controlled, double-blind study with two parallel groups including a total of 200 kidney transplant recipients, is designed to investigate the immunomodulatory and renoprotective effects of cholecalciferol (vitamin D3) within the transplant setting. Kidney transplant recipients found to have vitamin D deficiency defined as 25-hydroxyvitamin D3 < 50 nmol per liter will be randomly assigned to receive either oral cholecalciferol therapy or placebo and will be followed for one year. Cholecalciferol will be administered at a dose of 6800 International Units daily over a time period of one year. The objective is to evaluate the influence of vitamin D3 substitution in vitamin D deficient kidney transplant recipients on the post-transplant outcome. As a primary endpoint glomerular filtration rate calculated with the MDRD formula (modification of diet in renal disease) one year after kidney transplantation will be evaluated. Incidence of acute rejection episodes, and the number and severity of infections (analyzed by means of C-reactive protein) within the first year after transplantation will be monitored as well. As a secondary endpoint the influence of vitamin D3 on bone mineral density within the first year post-transplant will be assessed. Three DXA analyses will be performed, one within the first four weeks post-transplant, one five months and one twelve months after kidney transplantation.

Indexed as

Kidney TransplantationAdministration, OralCholecalciferolDouble-Blind MethodGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunologic FactorsResearch DesignRisk AssessmentTime FactorsTreatment OutcomeVitamin D DeficiencyVitaminsCholecalciferolImmunologic FactorsVitamins

Identifiers

PMID19480654
PMCPMC2701431
OpenAlexW2093292994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.